The year is 2018 and the level of scientific knowledge is unquestionable.
In medicine in general, and in cardiology, in particular, advances in diagnoses are impressive, just as the therapeutic arsenal is extraordinary, either in clinical or surgical, conventional or alternative treatment.
[…]
The Brazilian Society of Cardiology and Hypertension: It’s Time for
Action
JardimPCBV. The Brazilian Society of Cardiology and Hypertension: It’s Time for
Action. Arq. Bras.
Cardiol. 2018;111(3):343-4.
Jardim,Paulo César B. Veiga. The Brazilian Society of Cardiology and Hypertension: It’s Time for
Action. Arq. Bras.
Cardiol., v. 111, n. 3, p. 343-344, Sep. 2018.
Jardim,P.C.B.V. (2018). The Brazilian Society of Cardiology and Hypertension: It’s Time for
Action. Arq. Bras.
Cardiol.,111(3), 343-344.
Jardim,Paulo César B. Veiga. The Brazilian Society of Cardiology and Hypertension: It’s Time for
Action. Arq. Bras.
Cardiol. [online]. 2018, vol. 111, n. 3, [cited 2025-09-06], pp.343-344. Available from: <https://abccardiol.org/en/article/the-brazilian-society-of-cardiology-and-hypertension-its-time-foraction/>. ISSN 0066-782X.
Figure 1
Dyslipidemia as a central element in atherosclerotic cardiovascular disease. ASCVD: atherosclerotic cardiovascular disease; LDL-C: low-density lipoprotein cholesterol. Limitations of statin-based therapy (non-exhaustive) include suboptimal LDL-C goal attainment, statin-associated adverse effects that may affect adherence, and potential drug interactions. Residual risk reflects the involvement of multiple underlying pathways.